The most talked about and market moving research calls around Wall Street are now in one place.
Here are today’s research calls that investors need to know, as compiled by The Fly
Top 5 Upgrades: – Keefe Bruyette upgraded Toll Brothers (TOL) to Outperform from Market Perform with a price target of $161, up from $158. The firm says the upgrade reflects Toll’s exposure to “resilient” luxury demand, its long-land inflation hedge, and improved fundamentals post the fiscal Q2 report. – UBS upgraded Arthur J. Gallagher (AJG) to Buy from Neutral with a price target of $250, down from $283.
The firm’s view is above consensus on margins by 70 basis points through 2026-2028 as UBS sees upside from AssuredPartners synergies and AI-driven cost savings being underestimated. – Citi upgraded PTC Therapeutics (PTCT) to Buy from Neutral with a price target of $108, up from $75, after a transfer in analyst coverage. The firm cites its bullish outlook for Sephience in phenylketonuria for the upgrade. – JPMorgan upgraded Par Technology (PAR) to Neutral from Underweight with a price target of $16, up from $12. The firm says that due to a technical error, its initiation report on May 29 overstated the share count of Par. – Canaccord upgraded FuelCell (FCEL) to Buy from Hold with a price target of $30, up from $12.